Benjamin F. Edwards & Company, Inc. Neurocrine Biosciences Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 226 shares of NBIX stock, worth $27,863. This represents 0.0% of its overall portfolio holdings.
Number of Shares
226
Previous 219
3.2%
Holding current value
$27,863
Previous $30,000
3.33%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding NBIX
# of Institutions
624Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.75 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.23 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$635 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$317 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$230 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...